Home » Authors » Cormac Sheridan

Articles by Cormac Sheridan

Newron Plans Extended Phase IIb Trial Of Safinamide In Parkinson's

Jan. 15, 2003

By Cormac Sheridan

Elan Names Wall Street Veteran As CEO To Lead Divestiture Plan

Jan. 8, 2003

By Cormac Sheridan

Elan Names Wall Street Veteran As CEO To Lead Divestiture Plan

Jan. 8, 2003

By Cormac Sheridan

Axovan, Biolipox Collaborate On GPCR-Binding Drug Discover

Jan. 1, 2003

By Cormac Sheridan

Axovan, Biolipox Collaborate On GPCR-Binding Drug Discover

Jan. 1, 2003

By Cormac Sheridan

Berna Biotech, Samsung Win Vietnamese Vaccines Project

Dec. 25, 2002

By Cormac Sheridan

Berna Biotech, Samsung Win Vietnamese Vaccines Project

Dec. 25, 2002

By Cormac Sheridan

Pharmexa Moving Pharmaccine For Cancer Into Phase II Studies

Dec. 18, 2002

By Cormac Sheridan

Pharmexa Moving Pharmaccine For Cancer Into Phase II Studies

Dec. 18, 2002

By Cormac Sheridan

Enkam Finalizing First Round, Planning For First Clinical Trial

Dec. 11, 2002

By Cormac Sheridan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...